This report describes efforts to develop and validate novel norepinephrine transporter reuptake inhibition assays using human neuroblastoma SK-N-BE(2)C cells in 24-well format. Before conducting the assays, the SK-N-BE(2)C cells were first evaluated for their ability to uptake [3H]norepinephrine and were shown to have a saturable uptake with a KM value of 416 nM. Using this determined KM value, reuptake inhibition assays were then conducted with a variety of ligands including antidepressants, as well as piperazine and phenyltropane derivatives. The results obtained with the SK-N-BE(2)C cells indicate that this model system can detect a range of ligand potencies, which compare well with other established transporter assays. Our data suggest that SK-N-BE(2)C cells have potential utility to serve as another model system to detect norepinephrine reuptake inhibition activity.
Development of norepinephrine transporter reuptake inhibition assays using SK-N-BE(2)C cells
Decker, A. M., & Blough, B. E. (2018). Development of norepinephrine transporter reuptake inhibition assays using SK-N-BE(2)C cells. Heliyon, 4(5), [e00633]. https://doi.org/10.1016/j.heliyon.2018.e00633
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Personal exposure to PM2.5 in different microenvironments and activities for retired adults in two megacities, China
Estimating global artisanal fishing fleet responses in an era of rapid climate and economic change
Estimating phylogenies from genomes